Literature DB >> 11028259

A review of the technical aspects of drug nebulization.

P P Le Brun1, A H de Boer, H G Heijerman, H W Frijlink.   

Abstract

Nebulizers are widely used for the inhalation of drug solutions in a variety of respiratory diseases. The efficacy of nebulizer therapy is influenced by a great number of factors, including the design of the device and the characteristics of the drug solution. Incorrect cleaning, maintenance and disinfection procedures may change the nebulizer performance in time, whereas patient factors can influence the lung deposition of the generated aerosol. In this review the technical aspects of nebulization of drug solutions will be discussed. Two main parameters are generally used to evaluate the performance of nebulizers: the droplet size distribution of the aerosol and the drug output rate. The droplet size distribution and the drug output rate are basically determined by the design and user conditions of the nebulizer. A higher gas flow of the compressor in a jet nebulizer or a higher vibration frequency of the piezo electric crystal in an ultrasonic nebulizer, decreases the droplet size. The choice of the type of nebulizer for nebulization of a certain drug solution may initially be based on laboratory evaluation. The major part of the mass or volume distribution should preferably correspond with aerodynamic particle diameters in the range of 1 to 5 micrometer. The intended drug output must be realized within a reasonable nebulization time (less than 30 min). From the drug output only a minor fraction will be deposited in the lung. The relation between in vitro and in vivo deposition is only partly understood and to date it has not been possible to predict drug delivery only from in vitro studies on nebulizers. Therefore, studies in patients should be performed before a drug solution for nebulization can be recommended for clinical practice. The mechanical properties of nebulizers are likely to change during use. An average utilization time of nebulizers is not available. Therefore, the performance of nebulizers should be checked periodically. Patient compliance in nebulizer therapy is relatively low. This is partly due to the fact that, at present, drug solutions for nebulizers cannot be administered efficiently within a short period of time. More efficient systems should be developed. If possible, nebulizers should be substituted to more efficient systems, e.g. dry powder inhalers or metered dose inhalers.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11028259     DOI: 10.1023/a:1008786600530

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  16 in total

1.  Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation.

Authors:  Jean C Sung; Lucila Garcia-Contreras; Jarod L Verberkmoes; Charles A Peloquin; Katharina J Elbert; Anthony J Hickey; David A Edwards
Journal:  Antimicrob Agents Chemother       Date:  2009-01-12       Impact factor: 5.191

Review 2.  Fugitive aerosols in the intensive care unit: a narrative review.

Authors:  Ciarraí O'Toole; Mary Joyce; James A McGrath; Andrew O'Sullivan; Miriam A Byrne; Ronan MacLoughlin
Journal:  Ann Transl Med       Date:  2021-04

3.  Effects of Temperature and Humidity on Laser Diffraction Measurements to Jet Nebulizer and Comparison with NGI.

Authors:  Xinghan Song; Junhua Hu; Shuyao Zhan; Rui Zhang; Wen Tan
Journal:  AAPS PharmSciTech       Date:  2015-07-14       Impact factor: 3.246

4.  Aerosol delivery into small anatomical airway model through spontaneous engineered breathing.

Authors:  Chun-Kai Lin; Yuan-Yuan Hsiao; Pulak Nath; Jen-Huang Huang
Journal:  Biomicrofluidics       Date:  2019-08-07       Impact factor: 2.800

5.  Nebulization of Single-Chain Tissue-Type and Single-Chain Urokinase Plasminogen Activator for Treatment of Inhalational Smoke-Induced Acute Lung Injury.

Authors:  Soraya Hengsawas Surasarang; Sawittree Sahakijpijarn; Galina Florova; Andrey A Komissarov; Christina L Nelson; Enkhbaatar Perenlei; Satoshi Fukuda; Marla R Wolfson; Thomas H Shaffer; Steven Idell; Robert O Williams
Journal:  J Drug Deliv Sci Technol       Date:  2018-04-30       Impact factor: 3.981

Review 6.  Administration of Inhaled Pulmonary Vasodilators to the Mechanically Ventilated Neonatal Patient.

Authors:  Michael D Davis; Steven M Donn; Robert M Ward
Journal:  Paediatr Drugs       Date:  2017-06       Impact factor: 3.022

7.  Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model.

Authors:  Jason T McConville; Kirk A Overhoff; Prapasri Sinswat; Jason M Vaughn; Bradi L Frei; David S Burgess; Robert L Talbert; Jay I Peters; Keith P Johnston; Robert O Williams
Journal:  Pharm Res       Date:  2006-05-05       Impact factor: 4.200

8.  Aerosol vaccination induces robust protective immunity to homologous and heterologous influenza infection in mice.

Authors:  Jennifer Humberd Smith; Paula Brooks; Scott Johnson; S Mark Tompkins; Koren M Custer; Debra L Haas; Raydel Mair; Mark Papania; Ralph A Tripp
Journal:  Vaccine       Date:  2011-02-05       Impact factor: 3.641

9.  Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery.

Authors:  Jean C Sung; Danielle J Padilla; Lucila Garcia-Contreras; Jarod L Verberkmoes; David Durbin; Charles A Peloquin; Katharina J Elbert; Anthony J Hickey; David A Edwards
Journal:  Pharm Res       Date:  2009-04-30       Impact factor: 4.200

10.  Screening test for silent aspiration at the bedside.

Authors:  Yoko Wakasugi; Haruka Tohara; Fumiko Hattori; Yasutomo Motohashi; Ayako Nakane; Shino Goto; Yukari Ouchi; Shinya Mikushi; Syuhei Takeuchi; Hiroshi Uematsu
Journal:  Dysphagia       Date:  2008-07-02       Impact factor: 3.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.